Tengjun Biotechnology Corp.: 10-Q filed 2023-05-15

Name: Tengjun Biotechnology Corp.: 10-Q filed 2023-05-15
Creator: Tengjun Biotechnology Corp.

What Tengjun Biotechnology Corp. reported in its quarterly report filed 2023-05-15 (fiscal Q1 2023): 35 published measures, 71 facts as tagged in accession 0001213900-23-039845.

This filing

Form: 10-Q (quarterly report)
Filed: 2023-05-15
Fiscal period: fiscal Q1 2023
Accession: 0001213900-23-039845 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Tengjun Biotechnology Corp. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2023-03-31	173,921,171	USD
At 2022-12-31	58,629,500	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2023-03-31	158,152,748	USD
At 2022-12-31	43,656,963	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2023-03-31	15,217,411	USD
At 2022-12-31	14,455,397	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2023-03-31	12,014,466	USD
At 2022-12-31	2,830,646	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	362,667	USD	90
2022-01-01 to 2022-03-31	218,823	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	7,559,478	USD	90
2022-01-01 to 2022-03-31	1,260,939	USD	90

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	76,978	USD	90
2022-01-01 to 2022-03-31	2,384	USD	90

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	8,516,646	USD	90
2022-01-01 to 2022-03-31	4,284,114	USD	90

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	2,015,176	USD	90
2022-01-01 to 2022-03-31	190,716	USD	90

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	-384,760	USD	90
2022-01-01 to 2022-03-31	-48,473	USD	90

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2023-03-31	8,521,704	USD
At 2022-12-31	8,159,037	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	99,039,506	shares	90
2022-01-01 to 2022-03-31	65,309,169	shares	90

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	99,039,506	shares	90
2022-01-01 to 2022-03-31	65,309,169	shares	90

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	191,811	USD	90
2022-01-01 to 2022-03-31	92,955	USD	90

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2023-03-31	361,618	USD
At 2022-12-31	325,561	USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	575,986	USD	90
2022-01-01 to 2022-03-31	325,738	USD	90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2023-03-31	165,413,419	USD
At 2022-12-31	50,569,077	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2023-03-31	158,152,748	USD
At 2022-12-31	43,656,963	USD

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

Period	Value	Unit	Days
At 2023-03-31	1,064,493	USD
At 2022-12-31	1,001,028	USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	7,994,998	USD	90
2022-01-01 to 2022-03-31	3,914,050	USD	90

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2023-03-31	96,309,169	shares
At 2022-12-31	65,309,169	shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit
At 2023-03-31	12,014,466	USD
At 2022-12-31	2,830,646	USD
At 2022-03-31	1,690,839	USD
At 2021-12-31	285,568	USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2023-03-31	6,865,612	USD
At 2022-12-31	3,868,599	USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2023-03-31	-298,796	USD
At 2022-12-31	-420,376	USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

Period	Value	Unit
At 2023-03-31	15,768,423	USD
At 2022-12-31	14,972,537	USD
At 2022-03-31	-2,062,361	USD
At 2021-12-31	-2,285,730	USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

Period	Value	Unit	Days
At 2023-03-31	1,672,715	USD
At 2022-12-31	1,574,718	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2023-03-31	1,311,097	USD
At 2022-12-31	1,249,157	USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	390,587	USD	90
2022-01-01 to 2022-03-31	232,807	USD	90

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	484,247	USD	90
2022-01-01 to 2022-03-31	209,862	USD	90

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	45,210	USD	90
2022-01-01 to 2022-03-31	84,111	USD	90

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	-5,480	USD	90

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	7,419,012	USD	90
2022-01-01 to 2022-03-31	3,588,312	USD	90

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	277,767	USD	90

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	50,107	USD	90
2022-01-01 to 2022-03-31	-258,837	USD	90

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	4,606	USD	90

Inspect the source

Entity: Tengjun Biotechnology Corp. / CIK 0001499785
Captured: 2026-09-22 19:49 UTC
SEC response SHA-256: a2795bc9845e0dcc205ac5cf3a3b222f4e36b007201c1cdd329ca178677114b6

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001499785.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))